Stockhead’s Fraser Palamara chats with Imagion Biosystems (ASX:IBX) executive chairman Robert Proulx to discuss the company’s cancer-detecting imaging agent technology.

Fraser and Robert discuss the current state of the technology, difficulties in detection, and how it is advancing the sector to where a physician can deliver a diagnosis before advancing to more invasive procedures.

The company is moving into its next phase, so tune in to hear its successful proof of concept and what’s coming next on the milestones for a pivotal phase 2 study in the United States.

 

This video was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing.

 

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Read MoreAusbiotechBiotech

Featured Companies

You might be interested in